Joel D Leverson Selected Research

Joel D Leverson Research Topics

Disease

37	Neoplasms (Cancer) 01/2022 - 04/2005
11	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 12/2023 - 02/2013
7	Acute Myeloid Leukemia (Acute Myelogenous Leukemia) 12/2023 - 03/2014
7	Multiple Myeloma 12/2023 - 10/2015
5	Hematologic Neoplasms (Hematological Malignancy) 12/2023 - 11/2009
5	Leukemia 01/2020 - 03/2015
4	Lymphoma (Lymphomas) 01/2020 - 02/2013
4	Lung Neoplasms (Lung Cancer) 11/2018 - 01/2015
3	B-Cell Lymphoma (Lymphoma, B Cell) 01/2022 - 07/2015
2	Myelodysplastic Syndromes (Myelodysplastic Syndrome) 05/2022 - 01/2022
2	Carcinogenesis 01/2021 - 04/2005
2	Breast Neoplasms (Breast Cancer) 01/2019 - 08/2015
2	Ovarian Neoplasms (Ovarian Cancer) 01/2019 - 01/2017
1	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022
1	Disease Progression 01/2022
1	Squamous Cell Carcinoma of Head and Neck 01/2022
1	Synovial Sarcoma (Synovioma) 05/2021
1	Triple Negative Breast Neoplasms 11/2020
1	Hypersensitivity (Allergy) 01/2019
1	Ewing Sarcoma (Sarcoma, Ewing) 01/2019
1	BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia) 01/2016
1	Lymphadenopathy 10/2015
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 10/2015
1	Colorectal Neoplasms (Colorectal Cancer) 07/2015
1	Neutropenia 03/2015
1	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2015
1	Small Cell Lung Carcinoma (Small Cell Lung Cancer) 10/2014
1	Thrombocytopenia (Thrombopenia) 10/2014
1	Genomic Instability 09/2007
1	Weight Loss (Weight Reduction) 06/2005

Drug/Important Bio-Agent (IBA)

27	venetoclaxIBA 12/2023 - 02/2013
17	Proteins (Proteins, Gene)FDA Link 12/2023 - 09/2007
16	navitoclaxIBA 01/2022 - 12/2011
3	Phosphotransferases (Kinase)IBA 11/2018 - 06/2005
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2023 - 01/2018
2	Apoptosis Regulatory ProteinsIBA 01/2022 - 01/2018
2	Immunoconjugates (Immunoconjugate)IBA 11/2020 - 01/2019
2	Doxorubicin (Adriamycin)FDA LinkGeneric 10/2020 - 01/2015
2	DNA (Deoxyribonucleic Acid)IBA 01/2020 - 04/2005
2	cobimetinibIBA 01/2020 - 01/2019
2	Small Interfering RNA (siRNA)IBA 08/2015 - 04/2005
2	A-1155463IBA 07/2015 - 10/2014
2	Docetaxel (Taxotere)FDA Link 03/2015 - 01/2015
1	Mevalonic Acid (Mevalonate)IBA 12/2023
1	SenotherapeuticsIBA 01/2022
1	enasidenibIBA 01/2022
1	NF-kappa B (NF-kB)IBA 01/2022
1	Cisplatin (Platino)FDA LinkGeneric 01/2022
1	Agammaglobulinaemia Tyrosine KinaseIBA 12/2021
1	ibrutinibIBA 12/2021
1	MTOR InhibitorsIBA 11/2021
1	S63845IBA 05/2021
1	Oncogene Proteins (Oncogene Protein)IBA 01/2021
1	ErbB Receptors (EGF Receptor)IBA 11/2020
1	ABT-414IBA 11/2020
1	A-1331852IBA 10/2020
1	Etoposide (VP 16)FDA LinkGeneric 10/2020
1	CytokinesIBA 01/2020
1	Metformin (Glucophage)FDA LinkGeneric 01/2019
1	Drug CombinationsIBA 01/2019
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 01/2019
1	olaparibIBA 01/2019
1	EWS-FLI fusion proteinIBA 01/2019
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 01/2019
1	Oxidoreductases (Dehydrogenase)IBA 01/2018
1	Coenzyme A (CoA)IBA 01/2018
1	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	Myeloid Cell Leukemia Sequence 1 ProteinIBA 11/2017
1	Bortezomib (Velcade)FDA Link 01/2016
1	bcr-abl Fusion ProteinsIBA 01/2016
1	A-1210477IBA 08/2015
1	alvocidib (flavopiridol)IBA 08/2015
1	CamptothecinIBA 01/2015
1	BenzimidazolesIBA 01/2015
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 11/2009
1	UbiquitinIBA 09/2007
1	Glucose (Dextrose)FDA LinkGeneric 06/2005
1	Paclitaxel (Taxol)FDA LinkGeneric 06/2005
1	Sirolimus (Rapamycin)FDA Link 06/2005
1	Polo-Like Kinase 1IBA 04/2005
1	AgarIBA 04/2005

Therapy/Procedure

21	Therapeutics 05/2022 - 04/2005
7	Drug Therapy (Chemotherapy) 01/2022 - 01/2017
1	Chemoradiotherapy 01/2022
1	Combination Drug Therapy (Combination Chemotherapy) 05/2021